Alvotech announced that its commercialization partner Fuji Pharma Co., Ltd. has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies' exclusive commercialization partnership.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.72% | -4.44% | -12.08% |
2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.08% | 236M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- 4554 Stock
- News Fuji Pharma Co., Ltd.
- Fuji Pharma Co., Ltd. Submits Application for Marketing Approval of First Biosimilar Candidate in Japan